Cargando…
Neuroimaging, Urinary, and Plasma Biomarkers of Treatment Response in Huntington’s Disease: Preclinical Evidence with the p75(NTR) Ligand LM11A-31
Huntington’s disease (HD) is caused by an expansion of the CAG repeat in the huntingtin gene leading to preferential neurodegeneration of the striatum. Disease-modifying treatments are not yet available to HD patients and their development would be facilitated by translatable pharmacodynamic biomark...
Autores principales: | Simmons, Danielle A., Mills, Brian D., Butler III, Robert R., Kuan, Jason, McHugh, Tyne L. M., Akers, Carolyn, Zhou, James, Syriani, Wassim, Grouban, Maged, Zeineh, Michael, Longo, Frank M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8423954/ https://www.ncbi.nlm.nih.gov/pubmed/33786806 http://dx.doi.org/10.1007/s13311-021-01023-8 |
Ejemplares similares
-
TSPO–PET imaging using [(18)F]PBR06 is a potential translatable biomarker for treatment response in Huntington’s disease: preclinical evidence with the p75(NTR) ligand LM11A-31
por: Simmons, Danielle A, et al.
Publicado: (2018) -
A Small Molecule p75(NTR) Ligand, LM11A-31, Reverses Cholinergic Neurite Dystrophy in Alzheimer's Disease Mouse Models with Mid- to Late-Stage Disease Progression
por: Simmons, Danielle A., et al.
Publicado: (2014) -
p75(NTR) in Huntington's disease: beyond the basal ganglia
por: Brito, Verónica, et al.
Publicado: (2015) -
Impaired striatal function in Huntington's disease is due to aberrant p75NTR signaling
por: Plotkin, Joshua L, et al.
Publicado: (2014) -
A small molecule p75(NTR) ligand normalizes signalling and reduces Huntington’s disease phenotypes in R6/2 and BACHD mice
por: Simmons, Danielle A., et al.
Publicado: (2016)